AstraZeneca Pharma India Limited (BOM:506820)
India flag India · Delayed Price · Currency is INR
6,387.90
+93.00 (1.48%)
At close: Nov 6, 2026

AstraZeneca Pharma India Cash Flow Statement

Millions INR. Fiscal year is Apr - Mar.

Operating Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Income
1,7771,8751,1571,615992.9616
Depreciation & Amortization
193.6279.2385.4148.1162.6169.5
Other Amortization
6.66.614.51.3--
Loss (Gain) From Sale of Assets
-32.2-1.6-3.2-0.3-24.9-28.2
Asset Writedown & Restructuring Costs
-2.655.4617.812.4--
Stock-Based Compensation
4.410.951.427.423.718.2
Provision & Write-off of Bad Debts
193.3179.96.654.41742.9
Other Operating Activities
-336.5-383.2-544.1-298-286.5-139.3
Change in Accounts Receivable
-837.4-458.1-316.8-511.8-231.7-49
Change in Inventory
-2,564-4,788-3,206-376.7-499.9195.8
Change in Accounts Payable
4,2483,2642,598-313.7374.4120.5
Change in Other Net Operating Assets
178.7-191.4-107.3-79.555.361.6
Operating Cash Flow
2,830-151.4653.6278.7582.91,008
Operating Cash Flow Growth
--134.52%-52.19%-42.17%-3.80%

Investing Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Capital Expenditures
-168.6-15.6-17.5-107.6-85.2-96.2
Sale of Property, Plant & Equipment
1.32.77.14.134.832.5
Other Investing Activities
163.6199.8318.4320.9231.5111.1
Investing Cash Flow
-3.7186.9308217.4181.147.4

Financing Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Long-Term Debt Repaid
--74.8-41.3-38.6-38.5-35.1
Lease Payments
-112.4-74.8-41.3-38.6-38.5-35.1
Total Debt Repaid
-112.4-74.8-41.3-38.6-38.5-35.1
Net Debt Issued (Repaid)
-112.4-74.8-41.3-38.6-38.5-35.1
Common Dividends Paid
-900-800-600-400-200-50
Other Financing Activities
-69.4-44.9-14.6-5.2-6.3-9.5
Financing Cash Flow
-1,082-919.7-655.9-443.8-244.8-94.6

Net Cash Flow

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Cash Flow
1,744-884.2305.752.3519.2960.8

Free Cash Flow

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
2,661-167636.1171.1497.7911.8
Free Cash Flow Growth
--271.77%-65.62%-45.42%-6.07%
Free Cash Flow Margin
10.20%-0.73%3.71%1.32%4.96%11.32%
Free Cash Flow Per Share
106.44-6.6825.446.8419.9136.47
Levered Free Cash Flow
2,455-434.291,391-37.96762.44901.26
Unlevered Free Cash Flow
2,499-406.231,400-30.46766.38907.2
Free Cash Flow After Leases
2,549-241.8594.8132.5459.2876.7

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash Interest Paid
44.944.914.65.26.39.5
Cash Income Tax Paid
833.1833.1641.9564.3408.2247.9
Change in Working Capital
1,026-2,174-1,032-1,282-301.9328.9